Education
About Us
Working with TipRanks
Follow Us
GRAIL Inc (GRAL)
NASDAQ:GRAL
GRAL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.33 - $63.99
Previous CloseN/A
Volume371.20K
Average Volume (3M)1.22M
Market Cap
$1.05B
Enterprise Value-$90.33M
Total Cash (Recent Filing)$214.23M
Total Debt (Recent Filing)$68.14M
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Aug 19, 2025EPS Estimate
-4.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-64.76
Shares Outstanding35,296,860
10 Day Avg. Volume1,240,776
30 Day Avg. Volume1,215,215
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.98
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.16
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$26.00Price Target Upside-12.43% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
GRAIL Inc News
PremiumCompany Announcements
Grail Inc. Reports Strong Galleri Revenue Growth Amid Net LossPremiumCompany Announcements
GRAIL Inc. Reports Strong Growth and Strategic Advances---
Bulls Say, Bears Say
Bulls Say
Market OpportunityGRAIL has a first-mover advantage in the multi-cancer early detection (MCED) testing market, driven by its leading generation of clinical data and large addressable market.
PartnershipsNew strategic partnerships with Quest Diagnostics and TRICARE Health Insurance are expected to expand Grail Inc's reach and grow the market ahead of significant study readouts.
Technology And InnovationGRAIL's unique technology, protected by robust intellectual property, enables more efficient early cancer detection in asymptomatic individuals compared to other approaches.
Bears Say
Commercialization RisksThere are inherent risks associated with broadly commercializing novel technologies such as MCEDs, including an uncertain regulatory and reimbursement pathway.
Financial ConcernsManagement is making early progress extending the cash runway with ~$850MM currently in hand, but there is potential for ~$400MM in annual burn, which is well above management targets.
Regulatory ChallengesBroad reimbursement and adoption hinge on the NHS-Galleri readout and subsequent FDA approval, which are several years away.
---
Ownership Overview
29.47% Insiders
12.66% Mutual Funds
1.11% Other Institutional Investors
47.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $12.33 and its highest was $63.99 in the past 12 months.
What is GRAIL Inc’s market cap?
GRAIL Inc’s market cap is $1.05B.
When is GRAIL Inc’s upcoming earnings report date?
GRAIL Inc’s upcoming earnings report date is Aug 19, 2025 which is in 116 days.
How were GRAIL Inc’s earnings last quarter?
GRAIL Inc released its earnings results on Feb 20, 2025. The company reported -$2.89 earnings per share for the quarter, beating the consensus estimate of -$4.973 by $2.083.
Is GRAIL Inc overvalued?
According to Wall Street analysts GRAIL Inc’s price is currently Overvalued.
Does GRAIL Inc pay dividends?
GRAIL Inc does not currently pay dividends.
What is GRAIL Inc’s EPS estimate?
GRAIL Inc’s EPS estimate is -4.97.
How many shares outstanding does GRAIL Inc have?
GRAIL Inc has 35,296,860 shares outstanding.
What happened to GRAIL Inc’s price movement after its last earnings report?
GRAIL Inc reported an EPS of -$2.89 in its last earnings report, beating expectations of -$4.973. Following the earnings report the stock price went down -14.719%.
Which hedge fund is a major shareholder of GRAIL Inc?
Currently, no hedge funds are holding shares in GRAL
---
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.00 (-12.43% Downside)
$26.00 (-12.43% Downside)
Blogger Sentiment
Bullish
GRAL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $445.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-65.92%
Trailing 12-Months
Asset Growth
-31.04%
Trailing 12-Months
Company Description
GRAIL Inc
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
---
GRAL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in Galleri revenue, improvements in cost efficiency, and strategic partnerships, while also noting a substantial net loss for the full year and a decrease in development services revenue. The company is focused on reducing cash burn and has a strong cash position. Overall, the positive aspects outweigh the negatives.Read More>---
GRAL Stock 12 Month Forecast
Average Price Target
$26.00
▼(-12.43% Downside)
Technical Analysis
Best Analysts Covering GRAL
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
initiated a buy rating 4 days ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
---